INTS Intensity Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why INTS matters now
Intensity Therapeutics, Inc. (INTS) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.90 with +2.62% on the session and $9.2M in market capitalization; recent performance reads 1-month -14.60% and YTD -61.79%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.4M, and EPS of $-0.96. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -122.7%.
The latest indexable market news headline is "Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $125.00; recent insider activity includes BENDER LEWIS H filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
9.95
P/S
0.00
EV/EBITDA
0.35
DCF Value
$0.83
FCF Yield
-122.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-136.8%
ROA
-87.0%
ROIC
-110.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.4M | $-0.96 |
| Q4 2025 | $0.00 | $-3.1M | $-1.21 |
| FY 2025 | $0.00 | $-11.6M | $-8.56 |
| Q3 2025 | $0.00 | $-2.7M | $-1.55 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$125.00
Target (Median)
$125.00
Target Range
$125.00 - $125.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
3.06
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.